These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36996313)

  • 1. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins.
    Ng YLD; Bricelj A; Jansen JA; Murgai A; Peter K; Donovan KA; Gütschow M; Krönke J; Steinebach C; Sosič I
    J Med Chem; 2023 Apr; 66(7):4703-4733. PubMed ID: 36996313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
    Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
    Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNIPERs-Hijacking IAP activity to induce protein degradation.
    Naito M; Ohoka N; Shibata N
    Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted protein degradation and drug discovery.
    Naito M
    J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
    Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
    Belcher BP; Ward CC; Nomura DK
    Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
    Baker IM; Smalley JP; Sabat KA; Hodgkinson JT; Cowley SM
    Biochemistry; 2023 Feb; 62(3):645-656. PubMed ID: 35948047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.
    Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW
    J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
    Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E3 ligase ligand optimization of Clinical PROTACs.
    Jiang H; Xiong H; Gu SX; Wang M
    Front Chem; 2023; 11():1098331. PubMed ID: 36733714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.